Phase Ia/Ib dose-escalation study of the anti-TIGIT  tiragolumab as a single agent and in combination with atezolizumab in advanced solid tumors - Johanna C Bendell #AACR20 $RHHBY $MRK $RCUS $MREO $SGEN 7/x

conclusion 2/2
ORR 46% in PD-L1 +ve n=13 NSCLC https://t.co/eCwJmZmhza